Ensign Peak Advisors
SABS icon

Ensign Peak Advisors’s SAB Biotherapeutics SABS Stock Holding History

Ensign Peak Advisors’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.11M Sell
980,105
-192,536
-16% -$700K 0.01% 669
2026
Q2 		$4.57M Sell
1,172,641
-202,969
-15% -$755K 0.01% 583
2026
Q1 		$5.27M Buy
+1,375,610
New +$5.49M 0.01% 522

Other funds holding SABS

Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Polymer Capital Management (HK)
Polymer Capital Management (HK) Hong Kong $1.06B AUM 138.97% 1-Year Est. Return
HB Wealth Management
HB Wealth Management Atlanta, Georgia $19.5B AUM 16.96% 1-Year Est. Return
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $96.6B AUM 22.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return

Ensign Peak Advisors's SABS Position: Q3 2026 in Review

Ensign Peak Advisors reduced its SAB Biotherapeutics (SABS) stake by 16% in Q3 2026, selling an estimated $700K and leaving 980,105 shares worth $3.11M. The position accounts for 0.01% of the portfolio, ranked #669.

Ensign Peak Advisors first reported a position in SABS in Q1 2026 and has held it in 3 quarters since. The position peaked at $5.27M in Q1 2026. 45 funds tracked by Wall St. Rank hold SABS as of Q3 2026.

  • Ensign Peak Advisors held 980,105 shares of SAB Biotherapeutics worth $3.11M as of Q3 2026.
  • Ensign Peak Advisors sold 192,536 SAB Biotherapeutics shares in Q3 2026, an estimated $700K.
  • SAB Biotherapeutics made up 0.01% of Ensign Peak Advisors's portfolio in Q3 2026, its #669 holding.
  • Ensign Peak Advisors first reported a position in SAB Biotherapeutics in Q1 2026 and has held it in 3 quarters since.
  • Ensign Peak Advisors's SAB Biotherapeutics position peaked at $5.27M in Q1 2026.
  • 45 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2026.

Based on Ensign Peak Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.